Ultime notizie per Ferrari (NYSE:RACE) Azioni

Ferrari

Ferrari designs, engineers, and manufactures some of the world's most expensive luxury cars. With supply carefully controlled to be below demand and a brand steeped in decades of motor racing history, a Ferrari is viewed as a status symbol. In 2024, the company sold 13,752 vehicles at an average price over EUR 480,000 with more than 70% of its vehicles being sold to existing Ferrari clients. Eighty-six percent of revenue is generated from the sale of cars and spare parts and 10% from sponsorship, commercial, and brand activities including racing and lifestyle activities. In 2024, the Europe, Middle East, and Africa region accounted for 47% of revenue, the Americas was 33%, mainland China, Hong Kong, and Taiwan was 8%, and the rest of Asia was 12%.

Ferrari logo

Equities

News

Markets

Movers

Media

General

RACE

Ferrari cambia strategia a causa dei dazi USA: cosa cambia per investitori, consumatori e le performance azionarie.

Ferrari sfida i dazi: come ha reagito il prezzo delle azioni alle nuove politiche

Government

Il titolo RACE in forte ribasso dopo l&#39;annuncio di nuove tariffe commerciali. Analizziamo le possibili conseguenze per il settore auto.

Ferrari crolla in Borsa: Trump annuncia i dazi, che succede al cavallino?

Earnings

Guidance

Trimestrale da record per la casa di Maranello: un&#39;analisi approfondita svela le ragioni del successo e valuta il potenziale del titolo.

Ferrari a tutta velocità: utili alle stelle. È il momento giusto per investire?

Ferrari NV

Race Oncology Ltd

Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) today announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock, payable on June 18, 2025, to shareholders of record at the close of business on June 4, 2025. This dividend payment represents a 7.7% increase to the quarterly cash dividend paid in June 2024.

Dividends

ODFL

Old Dominion Freight Line Board Raises Quarterly Cash Dividend By 7.7% From $0.26 To $0.28 Per Share

Cato (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATO#NYSE">CATO</a>) reported quarterly earnings of $0.17 per share. This is a 68.52 percent decrease over earnings of $0.54 per share from the same period last year. The company reported $170.24 million in sales this quarter. This is a 3.87 percent decrease over sales of $177.10 million the same period last year.

CATO

Cato Q1 EPS $0.17 Down From $0.54 YoY, Sales $170.24M Down From $177.10M YoY

Needham analyst Mike Cikos reiterates Cognyte Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) from Hold to Hold.

Reiteration

Analyst Ratings

CGNT

Needham Reiterates Hold on Cognyte Softwareto Hold

Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) sees FY2026 sales of $1.185 billion-$1.206 billion vs $1.19 billion analyst estimate.

LSPD

Lightspeed Commerce Sees FY2026 Sales $1.185B-$1.206B vs $1.19B Est

NeoGenomics Announced The Commercial Launch Of c-MET CDx For NSCLC, Its C-MET Companion Diagnostic Immunohistochemistry (IHC) Assay

Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases
Management to host conference call today at 8 am Eastern Time to discuss data
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demonstrating the potential to control stereochemistry. In addition, three presentations from contract development and manufacturing organizations (CDMOs) including Bachem, Nitto Avecia, and ST Pharm validated the transferability of Codexis' ligation processes to their in-house facilities.

CDXS

Codexis Presents Data At TIDES USA Showcasing Proprietary ECO Synthesis Platform's Ability To Support siRNA Manufacturing By Reducing Purification Costs, Improving Process Performance, And Demonstrating Potential To Control Stereochemistry

Lightspeed Commerce Sees FY26 Revenue Growth Of Approximately 10%-12%; Projects Gross Profit Growth Of Approximately 14%

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and raises the price target from $25 to $31.

Price Target

MDWD

HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $31

AAP: 26% &#x7C; <a href="https://www.benzinga.com//node/45561098">Advance Auto Parts shares are trading higher following better-than-expected Q1 financial results.</a>
&nbsp;
URBN: 18% &#x7C; <a href="https://www.benzinga.com//node/45560639">Urban Outfitters shares are trading higher following better-than-expected Q1 financial results.</a>
&nbsp;
NVTS: 238% &#x7C; <a href="https://www.benzinga.com//node/45552685">Navitas Semiconductor Collaborates With NVIDIA On Next-Gen 800V HVDC Architecture Using GaNFast And GeneSiC Technologies To Power AI Systems Like Rubin Ultra</a>

Trading Ideas

NVTS

URBN

Market-Moving News for May 22nd

<ul>
<li>2025 Full Year Total Revenue Guidance of $94 to $98 million</li>
<li>Delcath Announces Plan to Enter into National Medicaid Drug Rebate Agreement</li>
</ul>

DCTH

Delcath Systems Sees 2025 CHEMOSAT And HEPZATO KIT Revenue Climbing To $94M–$98M In 2025, Up Over 150% YoY, Sees 83%–85% Gross Margins

DA Davidson analyst Peter Heckmann downgrades Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) from Buy to Neutral and announces $226 price target.

Downgrades

GWRE

DA Davidson Downgrades Guidewire Software to Neutral, Announces $226 Price Target

Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) sees Q1 sales of $285.000 million-$290.000 million vs $288.45 million analyst estimate.

Lightspeed Commerce Sees Q1 Sales $285.000M-$290.000M vs $288.45M Est

Sionna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SION#NASDAQ">SION</a>), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that preclinical data assessing combinations of Sionna's nucleotide-binding domain 1 (NBD1) stabilizers, SION-451 and SION-719, with complementary Sionna CFTR modulators, galicaftor (SION-2222) and SION-109, will be featured in an oral presentation at the European Cystic Fibrosis Society's (ECFS) 48th European Cystic Fibrosis Conference, being held June 4-7, 2025 in Milan, Italy.

SION

Sionna Therapeutics To Present Preclinical Data Assessing Combinations Of NBD1 Stabilizers, SION-451 And SION-719, With Complementary Sionna CFTR Modulators, Galicaftor And SION-109, At ECFS 48th European Cystic Fibrosis Conference

HC Wainwright &amp; Co. analyst Raghuram Selvaraju downgrades UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) from Buy to Neutral.

URGN

HC Wainwright & Co. Downgrades UroGen Pharma to Neutral

Sharps Technology, Inc. (Nasdaq: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces that it has received a notice from Nasdaq confirming that the Company has regained compliance with The Nasdaq's Capital Market's minimum bid price requirement of $1.00 per share and the minimum stockholders' equity requirement of $2.5 million.
The notice from Nasdaq indicates that the Company is in compliance with the Nasdaq Capital Market's listing requirements and the Company's common stock will continue to be listed and traded on Nasdaq.

STSS

Sharps Technology Regains Compliance With Nasdaq's Capital Market's Minimum Bid Price Requirement Of $1.00/Shr And Minimum Stockholders' Equity Requirement Of $2.5M

Analog Devices Sees Q3 Adj EPS $1.82-$2.02 vs $1.83 Est; Sees Sales $2.650B-$2.850B vs $2.62B Est

Needham analyst Ryan Koontz maintains Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) with a Buy and lowers the price target from $19 to $16.

VSAT

Needham Maintains Buy on Viasat, Lowers Price Target to $16

TLRY

Tilray Medical Announce The Launch Of Good Supply In Germany

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54258634&amp;newsitemid=20250522937132&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=5b94d70ee258ae97e4fbe9842247f4ab">Enanta Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 26-30, 2025 at the Bucharest International Conference Centre in Bucharest, Romania and online.
The E-Poster will highlight results from a Phase 2 study of zelicapavir, an oral, non-nucleoside small-molecule RSV-replication-inhibitor (N-protein), which were announced in December 2024, and include new data on the population PK/PD and time to viral load negativity.

ENTA

Enanta Pharma To Present Data From Phase 2 Study Of Zelicapavir In Children With Respiratory Syncytial Virus At 43rd Annual ESPID Meeting

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $180 price target.

AXSM

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target

Press Releases

DIVIDEND DISTRIBUTION PROPOSAL

FERRARI RELEASES ITS 2024 ANNUAL REPORT AND FILES ANNUAL REPORT ON FORM 20-F

Ferrari: Announcement of the Seventh Tranche of the Multi-Year Share Repurchase Program by Participating as a Purchaser in Exor's Accelerated Bookbuild Offering

Comments

Ferrari

Notizie

Ultime notizie per Ferrari (NYSE:RACE) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO